A new drug could change everything for children like seven-year-old daughter, Liliana, who has Prader-Willi syndrome, a rare ...
The Food and Drug Administration (FDA) has approved Vykatâ„¢ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
Griffith-Atkins, a therapist and the parent of a child with Prader-Willi syndrome, invites fellow caregivers to acknowledge ...
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...
The U.S. Food and Drug Administration approved Soleno Therapeutics' drug to treat a rare genetic disorder on Wednesday, ...
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results